About Hemostasis
Hemostasis is a company based in Saint Paul (United States) founded in 2006. It operates as a B2B. Hemostasis has completed 1 acquisition, including Fiagon. Hemostasis offers products and services including PosiSep® X, PosiSep® Hemostat, Accel®, NexStat®, and Vectra F ™. Hemostasis operates in a competitive market with competitors including Haemonetics, Vetex Medical, MediSieve, Immutrix Therapeutics and Glycologix, among others.
- Headquarter Saint Paul, United States
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website hemostasisllc.com
- Legal Name Hemostasis, Llc
- Investments & Acquisitions
Products & Services of Hemostasis
Hemostasis offers a comprehensive portfolio of products and services, including PosiSep® X, PosiSep® Hemostat, Accel®, NexStat®, and Vectra F ™.
Hemostat for sinus procedures to control bleeding and aid healing.
Device for nasal bleeding control with tissue separation capabilities.
Powder to stop bleeding in surgical environments quickly and effectively.
Topical powder for external wound hemostasis and patient care.
Micro-sponge for targeted drug delivery in medical treatments.
People of Hemostasis
5 people are tracked at Hemostasis (2 in leadership, 3 in team).
| Name | Role | Group |
|---|---|---|
Keith Roberts | Founder CEO | Leadership |
Chad Harris | Director Of Engineering | Leadership |
Ernie Hrad | Financial Controller | Team |
Jeff Valley | Quality Manager | Team |
Jeremy Nordling | Production Specialist | Team |
Complete people profiles for Hemostasis
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Hemostasis
Hemostasis has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Fiagon.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Clinical navigation systems for surgical applications to healthcare providers | fiagon.com | Hennigsdorf, Germany | 2007 | May 2022 | •••• |
Complete acquisition details for Hemostasis
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of Hemostasis
2 dated milestones of Hemostasis across 16 years, from founding to its latest funding, stage changes and deals.
- Founded Hemostasis is founded.
- Acquisition Acquires Fiagon.
Competitors of Hemostasis
Hemostasis operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Haemonetics, Vetex Medical, MediSieve, Immutrix Therapeutics and Glycologix, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| haemonetics.com | 1971 | Braintree, United States | – | 3,034 | Hematology products and solutions are provided for medical applications. | |
| vetexmedical.com | 2016 | Galway, Ireland | – | – | Catheters for venous clot management and removal are developed. | |
| medisieve.com | 2014 | London, United Kingdom | $4.18M | 12 | Magnetic therapy is developed to treat blood-borne diseases. | |
| immutrix.com | 2009 | Rapid, United States | $14.02M | – | Blood cleansing treatment device | |
| glycologix.com | 2016 | Beverly, United States | $3.25M | 7 | Biopolymers are developed for soft tissue protection and repair. | |
| recentcare.com.tw | 2013 | Taipei, Taiwan | – | – | Creates innovative wound care products using transdermal drug delivery systems. | |
| immunocept.com | 1999 | Denver, United States | $530,000 | – | Blood filtration therapy for severe sepsis is developed. |
Detailed competitors of Hemostasis
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Hemostasis
Complete news archive for Hemostasis
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Similar companies to Hemostasis
10 companies that operate in the same segment as Hemostasis (Hematology), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Catheter-based thrombectomy devices for vascular emboli removal are developed. | 2011 | Irvine, California, United States | USD 51.89 M | USD 493.63 M | 696 | |
Small activating RNA therapeutics are developed to restore gene function. | 2008 | London, England, United Kingdom | USD 460.41 M | USD 23.07 M | 37 | |
Small molecules are developed to treat hematologic and musculoskeletal disorders. | 2016 | Lexington, Kentucky, United States | USD 90 M | USD 244.06 M | 169 | |
Developer of Allogeneic cell therapy for cancer, autoimmune diseases and genetic blood disorders | 2016 | Menlo Park, California, United States | USD 442 M | – | 66 | |
Developer of therapeutics for the treatment of hematologic diseases | 2017 | Cambridge, Massachusetts, United States | USD 140 M | – | 84 | |
Gene therapy platform is developed for chronic disease treatments. | 2015 | Stevenage, Hertfordshire, United Kingdom | USD 273.69 M | USD 435.87 K | 152 | |
Novel anticoagulants for thrombosis treatment are developed. | 2019 | Cambridge, Massachusetts, United States | USD 250 M | – | 14 | |
Developer of therapies for treating hemochromatosis & beta thalassemia | 1989 | San Diego, California, United States | – | USD 75.72 M | 71 | |
Breakthrough therapies are developed for blood diseases and infections. | 2014 | Buffalo, New York, United States | USD 1 M | – | 22 | |
Hematology products and solutions are provided for medical applications. | 1971 | Braintree, Massachusetts, United States | – | USD 1.33 B | 3,020 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Hemostasis
Hemostasis was founded in 2006.
Hemostasis is headquartered in Saint Paul, United States. It is registered at Saint Paul, Minnesota, United States.
Hemostasis, LLC is a medical technology company specializing in hemostatic products made from chitosan biopolymers. They design and produce devices like PosiSep for controlling bleeding in surgical and hospital settings, collaborating with physicians to enhance efficacy and patient outcomes. Based in Saint Paul, Minnesota, USA, the company serves global healthcare providers by innovating wound healing solutions and offering products for various medical applications.
Hemostasis's top competitors include Haemonetics, Glycologix and Vetex Medical.
Hemostasis offers PosiSep® X, PosiSep® Hemostat, Accel®, NexStat®, and Vectra F ™.
Hemostasis has made 1 acquisition, including Fiagon.
Hemostasis operates through Hemostasis, Llc.